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Glutamine in critical care: current evidence from systematic reviews
Alison Avenell
Health Services Research Unit, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
Glutamine, the most abundant amino acid in the body, is thought to become conditionally
essential in critical illness. Some of the important roles for glutamine are as a carrier for inter-
organ N, a preferred fuel for enterocytes and cells of the immune system, a substrate for renal
NH3 formation and a precursor for glutathione. Mechanisms by which glutamine could improve
recovery include attenuating oxidant damage and inflammatory cytokine production, reducing
gut bacterial translocation and improving N balance. The present systematic review has found
trends to suggest that parenteral and enteral glutamine supplementation reduce mortality, the
development of infection and organ failure in critical illness. Trials of parenteral nutrition
containing glutamine with patients after elective surgery also suggest reduction of infection, but
it is unlikely that glutamine-containing parenteral nutrition would be used for such patients.
The evidence base is limited by the quality of the reported trials and the suggestion that there is
publication bias, with trials suggesting reduced infection being more likely to be published.
Glutamine: Randomised controlled trials: Systematic reviews: Meta-analyses:
Critical illness
The amino acid glutamine is the most abundant amino acid
in the body. Plasma levels fall in critical illness, suggesting
that glutamine could become limiting (Melis et al. 2004).
Parenteral glutamine supplementation improves N balance
(Stehle et al. 1989). Particular roles for glutamine include
inter-organ N transport, a N donor for nucleotides and
amino sugars and the key substrate for renal NH3 forma-
tion. As a preferred fuel for enterocytes, glutamine may
reduce bacterial translocation across the gut wall and thus
the risk of sepsis (Melis et al. 2004; De-Souza & Greene,
2005). Cells of the immune system also utilise glutamine
as fuel, and glutamine contributes to antioxidant defences
(Eaton, 2006), e.g. through the production of glutathione
(Melis et al. 2004). Glutamine enhances the expression of
heat-shock protein, which is very important for protection
against tissue damage in stress or injury (Singleton et al.
2005).
Until recently it has not been possible to include gluta-
mine in parenteral nutrition for reasons of stability, but it
is now possible. A systematic review of glutamine sup-
plementation in serious illness (critically-ill patients or
patients after surgery) published in 2002 (Novak et al.
2002) has found that glutamine supplementation in patients
after surgery may be associated with a reduction in infec-
tious complications and shorter hospital stay. In critical
illness glutamine appears to be associated with a reduc-
tion in complications and mortality. The greatest benefit
appears to relate to the use of high-dose parenteral gluta-
mine. The results of the meta-analyses are limited by the
poor quality of many of the reported studies.
More recently, the Canadian clinical practice guidelines
(Critical Care Connections Inc., 2005) for nutrition support
in mechanically-ventilated critically-ill adult patients have
recommended that where parenteral nutrition is prescribed
it should be supplemented with glutamine, and that enteral
glutamine should be considered for patients with burns
and trauma. However, glutamine-containing parenteral or
enteral nutrition has not been widely adopted in the UK
for critical illness or after surgery. There have been few
good-quality randomised controlled trials with adequate
statistical power to evaluate glutamine use in these patient
groups.
The response of patients after elective surgery and
critically-ill patients to glutamine may differ (Heyland
& Dhaliwal, 2005). In critical illness there is dramatic
over-amplification of the inflammatory response, probably
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together with cellular immune dysfunction, whereas after
surgery patients experience much less cytokine activation
and some suppression of cell-mediated immunity, which
increases the risk of infection. The present systematic re-
view considers separately critically-ill patients and patients
who have undergone surgery, as well as combining the
evidence from randomised controlled trials for these
patient groups.
Methods
A systematic review and meta-analyses were undertaken
of randomised controlled trials comparing glutamine-
containing parenteral or enteral nutrition with control feed-
ing. It was assumed that regimens given to intervention
and control groups were approximately isonitrogenous
and isoenergetic, but the amounts administered and
whether this assumption was valid was not always clear in
the reports. Trials evaluating immunonutrition feeding
regimens in which glutamine was one of several other
nutrients, e.g. arginine or n-3 fatty acids, were not inclu-
ded. Patient groups were adults with critical illness or post
surgery.
Trials were identified by searching five electronic data-
bases (Medline, Embase, CABNAR, Cinahl, Healthstar),
hand searching four journals (Clinical Nutrition, Journal
of Parenteral and Enteral Nutrition, Intensive Care
Medicine, Critical Care Medicine) and from previous
reviews, including that by Novak et al. (2002). Full pub-
lished reports, conference proceedings and abstracts
provided data. The last date for the search was August
2005.
Study or subcategory
Critical illness TPN
Dechelotte et al. (2002)
Fuentes-Orozco et al. (2004)
Goeters et al. (2002)
Ockenga et al. (2002)
Tjader et al. (2004)
Wischmeyer et al. (2001)
Ziegler et al. (2004)
Griffiths et al. (1997)
Subtotal (95 % CI)
Test for heterogeneity: χ2 8·68, df 7 (P =0·28), I 2 19·4 %
Total events: 61 (treatment), 73 (control)
Test for overall effect: Z 1·57 (P=0·12)
Test for overall effect: Z 0·45 (P=0·65)
Test for overall effect: Z 1·07 (P=0·29)
Test for overall effect: Z 0·00 (P=1·00)
Test for overall effect: Z 1·80 (P=0·07)
Total (95 % CI)
Total events: 133 (treatment), 157 (control)
Test for heterogeneity: χ2 15·78, df 14 (P =0·33), I 2 11·3 %
Surgical TPN
Mertes et al. (2000)
Subtotal (95 % CI)
Total events: 1 (treatment), 1 (control)
Test for heterogeneity: not applicable
Critical illness and surgical TPN
Powell-Tuck et al. (1999)
Subtotal (95 % CI)
Total events: 14 (treatment), 20 (control)
Test for heterogeneity: not applicable
Critical illness EN
Brantley & Pierce (2000)
Conejero et al. (2002)
Garrel et al. (2003)
Hall et al. (2003)
Houdijk et al. (1998)
Jones et al. (1999)
Subtotal (95 % CI)
Total events: 57 (treatment), 63 (control)
Test for heterogeneity: χ2 6·05, df 4 (P =0·20), I 2 33·9 %
n
16 58
2 17
72
14
30
15
31
42
279
11
0
11
2
1
18
9 56
3 16
72
14
10
16
32
42
258
21
1
4
5
5
25
1·72
0·63
0·52
0·33
0·92
0·43
0·21
0·72
0·75
0·83, 3·56
0·12, 3·28
0·27, 1·01
0·01, 7·55
0·38, 2·24
0·10, 1·88
0·03, 1·67
0·47, 1·11
0·52, 1·07
1·22
Not estimable
0·19
0·93
1·27
1·03
0·90
0·60, 2·51
0·05, 0·76
0·57, 1·49
0·30, 5·31
0·50, 2·08
0·58, 1·41
0·72 0·39, 1·32
1·00 0·07, 15·12
1·00 0·07, 15·12
0·81 0·65, 1·02
Favours treatment Favours control
0·1 0·2 0·5 1 2 5 10
0·72 0·39, 1·32
0 31
14 47
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41
26
345
14 83
83
2
27
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10
0 41
9 37
24
184
39
24
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25
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Fig. 1. A meta-analysis of glutamine-supplemented total parenteral nutrition (TPN) or enteral nutrition (EN) in critical illness and surgery to
show the relative risks (RR) for mortality. n, No. of patients affected in the treatment group or control group; N, total no. of patients in the
treatment group or control group. For details of analysis procedures, see p. 237 of proofs. , , Values extend beyond the range of values
shown.
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Data on deaths, participants with infection and par-
ticipants with organ failure are presented. A conservative
method of data handling was used. Outcomes were taken
from the last available time of follow-up, with a random-
effects model for meta-analysis. Data are presented with all
participants randomised as the denominator. Heterogeneity
amongst trials was assessed by the I2 statistic (Higgins
et al. 2003), where ‡50% was taken as indicating sig-
nificant heterogeneity. Publication bias was examined by
funnel-plot analysis (Sterne et al. 2001). Analyses were
undertaken using Review Manager version 4.2.7 software
(The Cochrane Collaboration, Oxford, UK). Relative risks
(RR) and 95% CI are reported.
Results
Fifteen trials were identified for patients with critical ill-
ness (including seven trials with a mixed intensive care
Study or subcategory
Critical illness TPN
Dechelotte et al. (2002)
Fuentes-Orozco et al. (2004)
Griffiths et al. (1997)
Ockenga et al. (2002)
Wischmeyer et al. (2001)
Ziegler et al. (2004)
de Beaux et al. (1998)
Subtotal (95 % CI)
Test for heterogeneity: χ2 11·11, df 6 (P =0·09), I 2 46·0 %
Total events: 62 (treatment), 84 (control)
Test for overall effect: Z 1·72 (P=0·09)
Test for overall effect: Z 2·27 (P=0·02)
Test for overall effect: Z 0·02 (P=0·99)
Test for overall effect: Z 2·85 (P=0·004)
Test for overall effect: Z 0·74 (P=0·46)
Test for overall effect: Z 3·11 (P=0·002)
Total events: 2 (treatment), 1 (control)
Total events: 192 (treatment), 251 (control)
Test for heterogeneity: χ2 1·25, df 5 (P =0·94), I 2 0 %
Test for heterogeneity: χ2 21·47, df 18 (P =0·26), I 2 16·2 %
Test for heterogeneity: not applicable
Surgical TPN
Surgical EN
Nitta et al. (2001)
Subtotal (95 % CI)
Total (95 % CI)
Jacobi et al. (1999)
Jiang et al. (1999)
Klek et al. (2005)
Neri et al. (2001)
O'Riordain et al. (1994)
Spittler et al. (2001)
Subtotal (95 % CI)
Total events: 15 (treatment), 32 (control)
Critical illness and surgical
Powell-Tuck et al. (1999)
Subtotal (95 % CI)
Total events: 37 (treatment), 38 (control)
Test for heterogeneity: not applicable
Critical illness EN
Conejero et al. (2002)
Garrel et al. (2003)
Hall et al. (2003)
Houdijk et al. (1998)
Subtotal (95 % CI)
Total events: 76 (treatment), 96 (control)
Test for heterogeneity: χ2 2·47, df 3 (P =0·48), I 2 0 %
10 58
4 17
42
14
15
31
7
184
28
4
7
8
1
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12 16
42
14
16
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7
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0
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0·14, 63·15
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0·27, 0·95
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1·00
0·38
0·14
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Fig. 2. A meta-analysis of glutamine-supplemented total parenteral (TPN) or enteral (EN) nutrition in critical illness and surgery to show
the relative risks (RR) for participants with infection. n, No. of patients affected in the treatment group or control group; N, total no. of patients
in the treatment group or control group. For details of analysis procedures, see p. 237 of proofs. , , Value extends beyond the range of
values shown.
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unit population, two trials with patients with trauma,
four trials with patients with pancreatitis or surgical
complications). There were eleven trials with patients who
had undergone elective surgery (nine trials with
patients undergoing gastrointestinal surgery (only one of
which indicated that patients required parenteral nutrition),
one trial with patients undergoing cystectomy, one trial
with patients having abdominal aortic aneurysm repair).
One further trial, undertaken in a UK hospital, evaluated
glutamine-containing parenteral nutrition with a mixed
hospital population cared for by the nutrition team
(Powell-Tuck et al. 1999). However, not all trials provided
data that could be incorporated into the meta-analyses.
Trial quality, as reported, was often limited, particu-
larly in terms of reporting concealment of randomisation,
intention-to-treat analysis and blinding of outcome assess-
ment (although this issue is not likely to be a problem for
reporting of deaths).
Mortality
Parenteral glutamine in critical illness was associated
with a non-significant reduction in mortality (RR 0.75
(95% CI 0.52, 1.07); Fig. 1). For enteral glutamine in
critical illness the RR was 0.90 (95% CI 0.58, 1.41). Only
one surgical trial reported mortality and one trial reported
for a mixed hospital population, in neither case was there a
significant reduction. Overall, for all population groups
combined the RR for mortality was 0.81 (95% CI 0.65,
1.02). Thus, there is a strong trend for a beneficial effect,
most clearly for parenteral glutamine in critical illness.
Participants with infection
For enteral glutamine in critical illness (often patients
with trauma or burns) there was a significant reduction
in infection among participants (RR 0.76 (95% CI
0.60, 0.96); Fig. 2). For parenteral glutamine in critical
illness there was a trend for a reduction in infections
(RR 0.71 (95% CI 0.49, 1.05)). In patients who had
undergone surgery and were given parenteral nutrition
containing glutamine, whether they required parenteral
nutrition or not, there was a significant reduction in infec-
tion among participants (RR 0.45 (95% CI 0.26, 0.78)).
Overall, for all patient groups there was a significant
reduction in infection among participants (RR 0.76 (95%
CI 0.64, 0.90)).
For the outcome of participants with infection, which
provides the most data, a funnel plot examining for the
suggestion of publication bias was undertaken (Fig. 3). The
individual data points should be evenly distributed in an
inverted ‘V’ on either side of the vertical axis. The plot
clearly shows fewer data points to the right of the line,
suggesting that small trials with positive results are more
likely to be published. The suggestion of publication bias
can be tested (Sterne et al. 2001); this test also suggests
publication bias (P = 0.03).
Participants with multi-organ or renal failure
Few trials have reported multi-organ or renal failure.
Combining all parenteral glutamine trials (Fig. 4) there
was a significant reduction (RR 0.67 (95% CI 0.46, 0.98)),
but not for enteral glutamine (RR 1.15 (95% CI 0.70,
1.87)). Overall, there was no suggestion that glutamine was
harmful in terms of multi-organ or renal failure (RR 0.82
(95% CI 0.61, 1.10)).
Conclusions
Overall, there is no suggestion that parenteral or enteral
glutamine is harmful, and trends in the data suggest bene-
ficial effects. However, the results have to be interpreted
with caution in view of the poor quality of the trials and
the suggestion from the funnel plot that trials with positive
results are more likely to be published. In addition, not all
trials reported all outcomes, so that even published trialists
may be selectively reporting outcomes.
The categorisation into critical illness or surgical trials
was not always straightforward. In the present analysis
trials in which the participants had pancreatitis or had
undergone surgery, followed by complications (e.g. peri-
tonitis), were classified as critical illness. However, it is
clear that almost all the surgical trials of parenteral gluta-
mine gave parenteral nutrition to patients after uncompli-
cated elective surgery, when parenteral nutrition would not
have been provided in clinical practice. Given that par-
enteral nutrition itself may be associated with an increased
risk of infection (Simpson & Doig, 2005), it is unclear how
the reduction in infection with parenteral glutamine for this
group of post-surgery patients can be interpreted.
There is clearly a need to evaluate the use of glutamine
further in adequately-powered randomised controlled trials
in critical illness and patients with surgical complications.
Trials in the UK, Canada and Sweden are being initiated to
examine the effect of parenteral glutamine, in parenteral
nutrition and supplementary to nutrition support.
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Fig. 3. Funnel-plot examination for publication bias for data from
the meta-analysis of glutamine-supplemented parenteral nutrition
(PN) or enteral nutrition (EN) in critical illness and surgery for the
relative risks for participants with infection (data shown in Fig. 2;
P = 0.03, suggesting publication bias).
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